Nocturnal sleep architecture disturbances in early methadone treatment patients

Xiao, Le; Tang, Yi-Lang; Smith, Alicia K.; Xiang, Yu‐Tao; Sheng, Lixia; Chi, Yong; Du, Wan-jun; Guo, Song; Jiang, Zhiquan; Zhang, Guofu; Luo, Xi

doi:10.1016/j.psychres.2009.02.003

Cited by 48 publications

(19 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It can lead to changes in sleep architecture including a reduction in sleep efficiency as well as slow wave sleep. 16 There also may be a reduction in rapid eye movement (REM) sleep. 17 These effects of chronic opioid ingestion on sleep architecture appear to be dose dependent and lead to poor sleep quality, resulting in daytime sleepiness.…”

Section: Discussionmentioning

confidence: 99%

“…17 These effects of chronic opioid ingestion on sleep architecture appear to be dose dependent and lead to poor sleep quality, resulting in daytime sleepiness. 1,[16][17][18][19] In addition to causing changes in sleep architecture, multiple studies have demonstrated that chronic use of opioids is associated with an increase in sleep-disordered breathing. 20,21 The use of chronic opioids can result in isolated symptoms (eg, snoring) and/or more severe abnormalities of respiration during sleep, including sleep-related hypoventilation, CSA and OSA.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Chronic Opioid Therapy and Sleep: An American Academy of Sleep Medicine Position Statement

Rosen

Aurora

Kirsch

et al. 2019

Journal of Clinical Sleep Medicine

View full text Add to dashboard Cite

There is a complex relationship among opioids, sleep and daytime function. Patients and medical providers should be aware that chronic opioid therapy can alter sleep architecture and sleep quality as well as contribute to daytime sleepiness. It is also important for medical providers to be cognizant of other adverse effects of chronic opioid use including the impact on respiratory function during sleep. Opioids are associated with several types of sleep-disordered breathing, including sleep-related hypoventilation, central sleep apnea (CSA), and obstructive sleep apnea (OSA). Appropriate screening, diagnostic testing, and treatment of opioidassociated sleep-disordered breathing can improve patients' health and quality of life. Collaboration among medical providers is encouraged to provide high quality, patient-centered care for people who are treated with chronic opioid therapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Chronic Opioid Therapy and Sleep: An American Academy of Sleep Medicine Position Statement

Rosen

Aurora

Kirsch

et al. 2019

Journal of Clinical Sleep Medicine

View full text Add to dashboard Cite

show abstract

“…Xiao et al [ 215 ] studied the quality of sleep in persons with heroin use disorder on early methadone maintenance therapy (MMT) after a median of 5.4 days of treatment [ 215 ]. Patients without pre-existing chronic sleep disturbances demonstrated lower ratings of sleep (Pittsburgh Sleep Quality Index [PSQI]) and daytime sleepiness (Epworth Sleepiness Scale [ESS]) compared to healthy sleepers.…”

Section: Opioidsmentioning

confidence: 99%

Sleep abnormalities associated with alcohol, cannabis, cocaine, and opiate use: a comprehensive review

Angarita

Emadi

Hodges

et al. 2016

Addict Sci Clin Pract

267

193

View full text Add to dashboard Cite

Sleep abnormalities are associated with acute and chronic use of addictive substances. Although sleep complaints associated with use and abstinence from addictive substances are widely recognized, familiarity with the underlying sleep abnormalities is often lacking, despite evidence that these sleep abnormalities may be recalcitrant and impede good outcomes. Substantial research has now characterized the abnormalities associated with acute and chronic use of alcohol, cannabis, cocaine, and opiates. This review summarizes this research and discusses the clinical implications of sleep abnormalities in the treatment of substance use disorders.

show abstract

“…Sleep impairments are common in OUD, including insomnia, disrupted sleep architecture, as well as sleep-related breathing disorders [21,50]. Sleep disturbances are also common in patients receiving OST, such as methadone and buprenorphine [51]. Poor sleep quality might negatively impact outcomes and adherence to addiction treatments, and impaired sleep promotes poor executive function and negative affect, which both increase relapse risk [52,53].…”

Section: Leveraging the Sleep-promoting Effects Of Suvorexant To Redumentioning

confidence: 99%

The dual orexin/hypocretin receptor antagonist suvorexant reduces addiction-like behaviors for the opioid fentanyl

O’Connor¹,

Fragale²,

James³

et al. 2020

Preprint

View full text Add to dashboard Cite

The orexin (hypocretin) system is critical for motivated seeking of all drugs of abuse, including opioids. In 2019, the National Institute on Drug Addiction (NIDA) identified the orexin system as a high priority target mechanism for novel pharmacological therapies to treat opioid use disorder (OUD).Suvorexant (Belsomra TM ) is a dual orexin receptor 1/orexin receptor 2 (OxR1/OxR2) antagonist that is FDA-approved for the treatment of insomnia, and thus has the potential to be readily repurposed for the treatment of OUD. However, studies have yet to test the therapeutic potential of suvorexant with respect to reducing opioid-related behaviors. Accordingly, here we investigated the efficacy of suvorexant in reducing several addiction-relevant behaviors in fentanyl self-administrating rats. In rats with limited drug experience, suvorexant decreased motivation for fentanyl on a behavioral economics (BE) task. This effect was greatest in rats with the highest motivation for fentanyl. Suvorexant was even more effective at decreasing motivation for fentanyl following induction of a more robust addiction phenotype by intermittent access (IntA) self-administration of the opioid. Suvorexant also attenuated punished responding for fentanyl and reduced cued reinstatement in IntA rats. Suvorexant did not affect general locomotor activity or natural reward seeking, indicating that at the doses used here, suvorexant can be used to reduce drug seeking with limited sedative or off-target effects. Together, these results highlight the therapeutic potential of suvorexant, particularly in individuals with the severe OUD.

show abstract

Nocturnal sleep architecture disturbances in early methadone treatment patients

Cited by 48 publications

References 41 publications

Chronic Opioid Therapy and Sleep: An American Academy of Sleep Medicine Position Statement

Chronic Opioid Therapy and Sleep: An American Academy of Sleep Medicine Position Statement

Sleep abnormalities associated with alcohol, cannabis, cocaine, and opiate use: a comprehensive review

The dual orexin/hypocretin receptor antagonist suvorexant reduces addiction-like behaviors for the opioid fentanyl

Contact Info

Product

Resources

About